Genomics of Drug Sensitivity in Cancer |
Linsitinib
|
Synonyms |
OSI-906, ASP-7487
|
Targets |
IGF1R
|
Target pathway |
IGFR signaling
|
PubCHEM ID |
11640390
|
Jsmol |
|
Download molecule |
11640390
|
PUBCHEM IUPAC INCHI |
InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)
|
Smiles |
OC6(CC(C4(=NC(C3(=CC2(=NC(C1(=CC=CC=C1))=CC=C2C=C3)))=C5(N4C=CN=C5N)))C6)(C)
|
Cluster number |
64
|
calculated LogS |
-6,927
|
Molecular weight |
421,503
|
calculated LogP |
4,0356
|
H-Acceptors |
6
|
H-Donors |
2
|
Ro5 violations |
0
|
Druglikeness |
1,7312
|
DrugScore |
0,2317372886602
|
Mutagenic |
none
|
Tumorigenic |
high
|
Reproductive Effective |
none
|
Irritant |
none
|
Fish Toxicity |
Low FHMT
|
Fish Toxicity2 |
1,7018
|
Rat Acute Toxicity |
2,6488
|
Acute Oral Toxicity |
III
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,5278
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Non-inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,487
|
AMES Toxicity |
AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Non-substrate
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Danger
|
Blood-Brain Barrier |
BBB+
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
Low HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Nucleus
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-3,2879
|